Shalby Ltd reported consolidated revenue from operations of Rs 2.72 billion for Q3 FY26, while net profit stood at Rs 17.7 million attributable to shareholders. The company approved financial results, a subsidiary rights issue subscription, and board-level changes during its February 11, 2026 meeting.
Healthcare services provider Shalby Ltd announced its unaudited financial results for the quarter and nine months ended December 31, 2025, following a board meeting held on February 11, 2026. The results were reviewed by the Audit Committee and subjected to limited review by statutory auditors TR Chadha & Co LLP.
For Q3 FY26, consolidated revenue from operations stood at Rs 2,721.26 million compared to Rs 2,756.33 million in the corresponding quarter last year. Consolidated net profit attributable to shareholders came in at Rs 17.65 million, while total comprehensive income attributable to shareholders showed a negative Rs 10.48 million.
On a standalone basis, revenue from operations was Rs 2,152.36 million and net profit stood at Rs 137.91 million for the quarter.
Key Highlights
-
Consolidated total income for Q3 FY26 stood at Rs 2,793.54 million
-
Consolidated profit before tax was Rs 92.30 million
-
Nine-month consolidated revenue reached Rs 8,539.85 million
-
Nine-month consolidated profit was Rs 162.33 million
-
Healthcare services generated Rs 2,419.75 million in Q3 revenue
-
Manufacturing and trading of implants contributed Rs 301.51 million
-
Board approved subscription of Rs 59.60 crore in PK Healthcare rights issue
-
Re-appointment of Independent Director for a second five-year term approved
-
Step-down subsidiary Ningen Lifecare to be closed through strike-off process
Shalby operates in healthcare services and implant manufacturing, with segment reporting under Ind AS 108. The company stated it is not classified as a large corporate under SEBI norms.
Source: Shalby Limited Regulatory Filing with NSE and BSE; TR Chadha & Co LLP Limited Review Report